Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
CH Geisler, MB van t'Veer, J Jurlander… - Blood, The Journal …, 2014 - ashpublications.org
Abstract The randomized Haemato Oncology Foundation for Adults in The Netherlands 68
phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 …
phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 …
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
This study assessed the safety and preliminary efficacy of escalated dose subcutaneous
alemtuzumab in combination with rituximab in chronic lymphocytic leukemia. Twenty-eight …
alemtuzumab in combination with rituximab in chronic lymphocytic leukemia. Twenty-eight …
[PDF][PDF] Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
FCA Frontline - 2014 - Citeseer
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3
trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal …
trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal …